Home › NDC Lookup › RxCUI directory › RxCUI 2122519

Dolutegravir 50 MG / lamivudine 300 MG Oral Tablet — RxCUI 2122519

RxNorm drug concept · Semantic clinical drug
RxCUI 2122519 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2122519
Official nameDolutegravir 50 MG / lamivudine 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdolutegravir 50 MG / 3TC 300 MG Oral Tablet; dolutegravir 50 MG (equivalent to 52.6 MG dolutegravir sodium) / lamivudine 300 MG Oral Tablet
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)103,012 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dolutegravir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dolutegravir blocks a step HIV needs to survive inside your body. The virus uses an enzyme called integrase to insert its genetic code into your cells — once it does that, your cel...
  • What exactly does dolutegravir do — how does it fight HIV?
  • You can take dolutegravir with or without food — there's no strict requirement. That said, food does increase how much of the medicine your body absorbs, so taking it with a meal c...
  • Can I take it with food, or does it have to be on an empty stomach?
📖 Read our full Dolutegravir guide →

🕸️ Concept Web — How Dolutegravir 50 MG / lamivudine 300 MG Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dolutegravir 50 MG / lamivudine 300 MG Oral Tablet RxCUI 2122519

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Dolutegravir 1433868
    • Lamivudine 68244
    • Dolutegravir / lamivudine 2122518
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Dovato 2122521
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dolutegravir / lamivudine Oral Tablet 2122517
    • Dolutegravir / lamivudine Oral Product 2122515
    • Dolutegravir / lamivudine Pill 2122516
    • Dolutegravir / lamivudine Oral Tablet [Dovato] 2122523
    • Dovato Oral Product 2122524
    • Dovato Pill 2122525
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dolutegravir 50 MG SCDC · 1433869
  • Lamivudine 300 MG SCDC · 350655
  • Dolutegravir / lamivudine Oral Tablet SCDF · 2122517
  • Dolutegravir / lamivudine Oral Product SCDG · 2122515
  • Dolutegravir / lamivudine Pill SCDG · 2122516

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 2122519 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0246-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13) Dovato ViiV Healthcare Company 2019-04-08
49702-0246-33 1 BLISTER PACK in 1 CARTON (49702-246-33) / 30 TABLET, FILM... Dovato ViiV Healthcare Company 2024-01-01
49702-0246-62 1 BLISTER PACK in 1 CARTON (49702-246-62) / 14 TABLET, FILM... Dovato ViiV Healthcare Company 2024-01-01
Observed labelers: ViiV Healthcare Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$105.2550
Range $105.2550–$105.2550 · middle 50% $105.2550–$105.2550 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.